Opportunity, Llc Vivo Oppor... Net Worth

The estimated Net Worth of Opportunity, Llc Vivo Oppor... is at least $150 million dollars as of 31 January 2022. Opportunity Oppor owns over 800,000 units of Sierra Oncology Inc stock worth over $150,444,556 and over the last 5 years Opportunity sold SRRA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Opportunity Oppor SRRA stock SEC Form 4 insiders trading

Opportunity has made over 1 trades of the Sierra Oncology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Opportunity bought 800,000 units of SRRA stock worth $21,600,000 on 31 January 2022.

The largest trade Opportunity's ever made was buying 800,000 units of Sierra Oncology Inc stock on 31 January 2022 worth over $21,600,000. On average, Opportunity trades about 266,667 units every 0 days since 2020. As of 31 January 2022 Opportunity still owns at least 2,735,853 units of Sierra Oncology Inc stock.

You can see the complete history of Opportunity Oppor stock trades at the bottom of the page.

Insiders trading at Sierra Oncology Inc

Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth et James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.

What does Sierra Oncology Inc do?

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Complete history of Opportunity Oppor stock trades at Sierra Oncology Inc

Sierra Oncology Inc executives and stock owners

Sierra Oncology Inc executives and other stock owners filed with the SEC include:

• Barbara Klencke,
  Chief Development Officer
• Mark Kowalski,
  Chief Medical Officer
• Sukhi Jagpal,
  Chief Financial Officer
• Dr. Stephen George Dilly M.B.B.S, Ph.D.,
  Pres, CEO & Director
• Dr. Barbara J. Klencke M.D.,
  Chief Medical Officer
• Dr. Mark M. Kowalski M.D., Ph.D.,
  Chief of Research & Early Devel.
• Robert Pelzer,
  Independent Chairman of the Board
• James Smith,
  Vice President Corporate Affairs
• Andrew Sinclair,
  Independent Director
• Josh Richardson,
  Independent Director
• Jeffrey Cooper,
  Independent Director
• Mona Ashiya,
  Independent Director
• Andrew Allen,
  Independent Director
• Gaurav Aggarwal,
  Independent Director
• Craig Collard,
  Director
• William Turner,
  Chief Regulatory and Technical Operations Officer
• Kevin Norrett,
  Chief Business Officer
• Christina Thomson,
  General Counsel
• Stephen Dilly,
  President, Chief Executive Officer, Director
• Kevin Norrett M.B.A., M.S.,
  Chief Bus. Officer
• William D. Turner,
  Chief Regulatory & Technical Operations Officer
• Christina Thomson J.D., M.S.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Sukhi Jagpal CA, CPA, CBV, MBA,
  Chief Financial Officer
• Daniel Estes,
  Director
• James N Topper,
  Director
• Nicholas Glover,
  CEO and President
• Nicole Onetto,
  Director
• Tran Nguyen,
  Director
• Donald R Parfet,
  Director
• Angie You,
  Chief Bus. & Strat. Officer
• Capital Partners Iii, Llc L...,
  
• Christian Hassig,
  Chief Scientific Officer
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llcorbimed Capital...,
  
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llc Orbi Med Capit...,
  
• Georgia Erbez,
  Director
• Christy J. Oliger,
  Director
• Llp Abingworth,
  10% owner
• Mary Christina Thomson,
  General Counsel
• Advisors Llc Orbi Med Capit...,